Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Seasonal variation in immune measurements and MRI markers of disease activity in MS.

Killestein J, Rep MH, Meilof JF, Adèr HJ, Uitdehaag BM, Barkhof F, van Lier RA, Polman CH.

Neurology. 2002 Apr 9;58(7):1077-80.

PMID:
11940696
2.

Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells.

Killestein J, Rep MH, Barkhof F, Roos MT, Adèr HJ, van Lier RA, Polman CH.

J Neuroimmunol. 2001 Aug 30;118(2):286-94.

PMID:
11498263
3.

Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients.

Rep MH, Schrijver HM, van Lopik T, Hintzen RQ, Roos MT, Adèr HJ, Polman CH, van Lier RA.

J Neuroimmunol. 1999 Apr 1;96(1):92-100.

PMID:
10227428
4.

Phenotypic and functional separation of memory and effector human CD8+ T cells.

Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, van Lier RA.

J Exp Med. 1997 Nov 3;186(9):1407-18.

5.
6.

Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells.

Rep MH, Hintzen RQ, Polman CH, van Lier RA.

J Neuroimmunol. 1996 Jul;67(2):111-8.

PMID:
8765333
7.

A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis.

van Oosten BW, Rep MH, van Lier RA, Scholten PE, von Blomberg BM, Pflughaupt KW, Hartung HP, Adèr HJ, Polman CH.

J Neuroimmunol. 1996 May;66(1-2):49-55.

PMID:
8964913

Supplemental Content

Support Center